Advanced Cell Diagnostics raises other $5.4m in its Series A equity financing

Advanced Cell Diagnostics has completed the second closing of its Series A equity financing from Morningside Ventures, bringing the total capital raised in this round to $5.4m.
The funds will allor the Hayward, Ca.-based company to further develop its cell- and tissue-based diagnostic tests. Advanced Cell Diagnostics’ products and services are based on its proprietary RNAscope(TM) technology, a multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity.

Dr. Yuling Luo, Founder, President and CEO of Advanced Cell Diagnostics said that this second closing will allow the company to offer its development expertise in RNA analysis for biomarker validation and companion diagnostic development in partnership with pharmaceutical and biotechnology companies”.



Join the discussion